US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sagimet Biosciences Inc.

3.63

+0.14004.01%

Pre-market: 5.251.62+44.63%05:47 EDT

Volume:2.02M

Turnover:7.32M

Market Cap:116.87M

PE:-2.04

High:3.74

Open:3.49

Low:3.45

Close:3.49

Loading ...

Overview Company News Filings

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne

Sagimet Biosciences Inc - Denifanstat Meets All Primary and Secondary Endpoints in Phase 3 Trial

THOMSON REUTERS

Sagimet Biosciences Inc -Denifanstat Was Well Tolerated

THOMSON REUTERS

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne From Partner Ascletis

THOMSON REUTERS

Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Janux Therapeutics Inc (JANX)

Sagimet Biosciences price target lowered to $25 from $30 at Oppenheimer

Sagimet Biosciences Reports Q1 2025 Financial Results

JonesTrading Keeps Their Buy Rating on Sagimet Biosciences, Inc. Class A (SGMT)

Sagimet Biosciences Q1 2025 EPS $(0.56) Beats $(0.65) Estimate, Cash, Cash Equivalents And Marketable Securities As Of March 31, 2025, Were $144.6M

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

THOMSON REUTERS

Top Penny Stocks To Watch In April 2025

Simply Wall St.

Holding(s) in Company

ProQR Appoints Dennis Hom as CFO, Cristina Lopez as CMO

MT Newswires Live

Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position

Sagimet Biosciences Price Target Announced at $32.00/Share by HC Wainwright & Co.

Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom

Sagimet Biosciences Advances MASH Treatment with New Trials

Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567

Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SGMT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SGMT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGMT\",,,,,undefined,":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":3.63,"timestamp":1748980800000,"preClose":3.49,"halted":0,"volume":2023482,"hourTrading":{"tag":"盘前","latestPrice":5.25,"preClose":3.63,"latestTime":"05:47 EDT","volume":533975,"amount":3037721.9940925,"timestamp":1749030443874},"delay":0,"floatShares":23084506,"shares":32195345,"eps":-1.777054,"marketStatus":"Pre-Mkt","change":0.14,"latestTime":"06-04 05:47:28 EDT","open":3.49,"high":3.74,"low":3.45,"amount":7317746.610066,"amplitude":0.083095,"askPrice":5.34,"askSize":25,"bidPrice":5.22,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.777054,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749043800000},"marketStatusCode":1,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":3.63,"preHourTrading":{"tag":"盘前","latestPrice":5.25,"preClose":3.63,"latestTime":"05:47 EDT","volume":533975,"amount":3037721.9940925,"timestamp":1749030443874},"postHourTrading":{"tag":"盘后","latestPrice":6.18,"preClose":3.63,"latestTime":"19:59 EDT","volume":1650798,"amount":9629576.5848,"timestamp":1748995199425},"volumeRatio":4.162924768342665,"impliedVol":1.5114,"impliedVolPercentile":0.2851},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGMT\",,,,,undefined,":{"symbol":"SGMT","floatShares":23084506,"roa":"-24.05%","roe":"-34.72%","lyrEps":-1.453459,"volumeRatio":4.162924768342665,"shares":32195345,"dividePrice":0,"high":3.74,"amplitude":0.083095,"preClose":3.49,"low":3.45,"week52Low":1.73,"pbRate":"0.84","week52High":7.38,"institutionHeld":0,"latestPrice":3.63,"committee":0.6,"eps":-1.777054,"divideRate":0,"volume":2023482,"delay":0,"ttmEps":-1.777054,"open":3.49,"prevYearClose":4.5,"prevWeekClose":3.55,"prevMonthClose":3.55,"prevQuarterClose":3.26,"fiveDayClose":3.36,"twentyDayClose":3.59,"sixtyDayClose":3.68},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SGMT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540053848","title":"Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2540053848","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540053848?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:00","pubTimestamp":1749027616,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase  inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9NgkYx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4112","01672","LU2210149790.SGD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4588","BK4585","SGMT","NDAQ","IE00B64PRP62.GBP","BK1161","BK1515","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2540675053","title":"Sagimet Biosciences Inc - Denifanstat Meets All Primary and Secondary Endpoints in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540675053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540675053?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:00","pubTimestamp":1749027600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nTUA9XTCZG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2540605367","title":"Sagimet Biosciences Inc -Denifanstat Was Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2540605367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540605367?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:00","pubTimestamp":1749027600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nTUA9XTCZG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2540505896","title":"Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne From Partner Ascletis","url":"https://stock-news.laohu8.com/highlight/detail?id=2540505896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540505896?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:00","pubTimestamp":1749027600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nTUA9XTCZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2540255557","title":"Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Janux Therapeutics Inc (JANX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540255557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540255557?lang=en_us&edition=fundamental","pubTime":"2025-06-03 16:10","pubTimestamp":1748938230,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report), Sagimet Bioscience...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-pfizer-pfe-sagimet-biosciences-inc-class-a-sgmt-and-janux-therapeutics-inc-janx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-pfizer-pfe-sagimet-biosciences-inc-class-a-sgmt-and-janux-therapeutics-inc-janx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0306806265.USD","LU1894683264.USD","BK4568","BK4139","BK4599","BK4534","LU0321505439.SGD","LU0321505868.SGD","LU0289739699.SGD","SGMT","SG9999002232.USD","LU0985481810.HKD","SG9999001176.USD","BK4533","JANX","LU0225771236.USD","BK4007","IE0002270589.USD","LU0225284248.USD","SG9999011175.SGD","LU0058720904.USD","SGXZ57979304.SGD","SG9999002224.SGD","BK4137","SG9999003800.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0456855351.SGD","LU0170899867.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","BK4588","LU1066053197.SGD","LU0234572021.USD","LU0306807586.USD","IE000M9KFDE8.USD","BK4581","IE00BLSP4239.USD","LU1894683348.USD","BK4550","LU0122379950.USD","BK4539","LU1066051498.USD","IE00B19Z3581.USD","PFE","LU0868494617.USD","HCSG","LU1057294990.SGD","BK4592","SG9999013999.USD"],"gpt_icon":0},{"id":"2535160788","title":"Sagimet Biosciences price target lowered to $25 from $30 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2535160788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535160788?lang=en_us&edition=fundamental","pubTime":"2025-05-13 02:05","pubTimestamp":1747073144,"startTime":"0","endTime":"0","summary":"Oppenheimer lowered the firm’s price target on Sagimet Biosciences (SGMT) to $25 from $30 and keeps an Outperform rating on the shares. Published f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-lowered-to-25-from-30-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-lowered-to-25-from-30-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","OPY"],"gpt_icon":0},{"id":"2534841583","title":"Sagimet Biosciences Reports Q1 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534841583","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534841583?lang=en_us&edition=fundamental","pubTime":"2025-05-10 12:16","pubTimestamp":1746850609,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has released its Q1 earnings. Here is a breakdown of the information Sagimet Biosciences, Inc. Class ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2534845775","title":"JonesTrading Keeps Their Buy Rating on Sagimet Biosciences, Inc. Class A (SGMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2534845775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534845775?lang=en_us&edition=fundamental","pubTime":"2025-05-10 03:25","pubTimestamp":1746818724,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) today. The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2533901879","title":"Sagimet Biosciences Q1 2025 EPS $(0.56) Beats $(0.65) Estimate, Cash, Cash Equivalents And Marketable Securities As Of March 31, 2025, Were $144.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2533901879","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533901879?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:14","pubTimestamp":1746699264,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Q1 2025 EPS $(0.56) Beats $(0.65) Estimate, Cash, Cash Equivalents And Marketable Securities As Of March 31, 2025, Were $144.6M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45279499/sagimet-biosciences-q1-2025-eps-0-56-beats-0-65-estimate-cash-cash-equivalents-and-marketable-secur","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2533032229","title":"Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2533032229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533032229?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:00","pubTimestamp":1746698401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA5NVZKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2530966470","title":"Top Penny Stocks To Watch In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530966470","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530966470?lang=en_us&edition=fundamental","pubTime":"2025-04-25 02:05","pubTimestamp":1745517911,"startTime":"0","endTime":"0","summary":"As the U.S. stock market experiences a surge, driven by positive earnings reports and anticipation of tariff news, investors are paying close attention to potential opportunities across various sectors. For those willing to explore beyond established giants, penny stocks—often representing smaller or newer companies—remain an intriguing option. Despite being considered somewhat outdated, these stocks can still offer significant growth potential when backed by strong financials and sound fundamentals. In this article, we highlight three penny stocks that stand out for their balance sheet strength and potential for impressive returns.Overview: Origin Materials, Inc. operates as a carbon-negative materials company with a market cap of $102.24 million.Click here and access our complete financial health analysis report to understand the dynamics of Origin Materials.Gain insights into Origin Materials' outlook and expected performance with our report on the company's earnings estimates.Overv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-penny-stocks-watch-april-180511198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SB","BK4209","BABB","BK4021","BK4509","ORGNW","TTI","BK4526","BK4563","TUYA","BK4023","BK4139","BK4179","SGMT","BK4505","ORGN","BK4090","PLX"],"gpt_icon":0},{"id":"2529549459","title":"Holding(s) in Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2529549459","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529549459?lang=en_us&edition=fundamental","pubTime":"2025-04-23 14:01","pubTimestamp":1745388060,"startTime":"0","endTime":"0","summary":"DIVERSIFIED ENERGY COMPANY PLC  announces that, in accordance with the terms of its share buyback programme announced on 20 March 2025, the Company has purchased 60,300 Ordinary Shares of 20 Pence each in the capital of the Company  in the market at a volume-weighted average price of $11.9682 per Share through Mizuho Securities USA LLC . The Shares acquired will, in due course, be cancelled.Following the cancellation of Shares, Diversified will have 80,498,562 Ordinary Shares of 20 Pence each in issue and no Ordinary Shares are held in treasury. This figure of 80,498,562 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.In accordance with Article 5 of Regulation  No 596/2014 , , the table below contains detailed information of the individual trades made by Peel Hunt as part of the buybac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/holding-company-060100494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USD","ARCX","DEC","BK4156","BK4213","SGMT","BK4139","EU"],"gpt_icon":0},{"id":"2527196615","title":"ProQR Appoints Dennis Hom as CFO, Cristina Lopez as CMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2527196615","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527196615?lang=en_us&edition=fundamental","pubTime":"2025-04-14 22:54","pubTimestamp":1744642499,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics  said Monday it appointed Dennis Hom as chief financial officer and Cristina Lopez as chief medical officer.Hom joins the company from Sagimet Biosciences , where he most recently was head of corporate development and CFO, ProQR added. He will succeed Jurriaan Dekkers, who is stepping down as finance chief but will remain during the transition period.Lopez most recently served as global head of neurodegeneration at Johnson & Johnson .ProQR's stock was down 2.2% in recent Monday trading.Price: 1.10, Change: -0.03, Percent Change: -2.23","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B2B36J28.USD","LU2129689514.USD","LU2430703178.SGD","LU0203347892.USD","LU1732800096.USD","BK4534","LU2592432038.USD","IE00B19Z3581.USD","LU0345769128.USD","BK4559","LU0058720904.USD","LU1057294990.SGD","LU2133065610.SGD","PRQR","IE0009355771.USD","LU1430594728.SGD","LU0985320562.USD","LU2347655156.SGD","LU2602419157.SGD","SG9999001440.SGD","IE00B7SZLL34.SGD","LU1929549753.HKD","LU1066053197.SGD","LU1267930813.SGD","LU1718418525.SGD","LU0114720955.EUR","IE00BDGV0183.EUR","LU1732799900.SGD","LU1032466523.USD","BK4533","LU1914381329.SGD","LU0098860793.USD","JNJ","LU0122379950.USD","LU2430703251.USD","SGMT","LU0912757837.SGD","LU2430703095.HKD","LU1221951129.SGD","LU1196500208.SGD","IE00B3PB1722.GBP","IE00BBT3K403.USD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","IE00BLSP4452.SGD","LU1066051811.HKD","BK4139","LU1244550221.USD","LU1506573853.SGD","LU0466842654.USD"],"gpt_icon":0},{"id":"2519819178","title":"Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2519819178","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519819178?lang=en_us&edition=fundamental","pubTime":"2025-03-14 10:55","pubTimestamp":1741920924,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A (SGMT) has received a new Buy rating, initiated by TD Cowen analyst, Ritu Baral. Ritu Baral has given her Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sagimet-biosciences-promising-future-with-phase-3-mash-trials-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sagimet-biosciences-promising-future-with-phase-3-mash-trials-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2519882553","title":"Sagimet Biosciences Price Target Announced at $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2519882553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519882553?lang=en_us&edition=fundamental","pubTime":"2025-03-13 18:43","pubTimestamp":1741862580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 06:43 ET (10:43 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2519160070","title":"Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom","url":"https://stock-news.laohu8.com/highlight/detail?id=2519160070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519160070?lang=en_us&edition=fundamental","pubTime":"2025-03-13 14:01","pubTimestamp":1741845696,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A (SGMT) has disclosed a new risk, in the Technology category. Sagimet Biosciences, Inc. Class A faces significant ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-faces-ai-integration-challenges-security-compliance-and-cost-risks-loom?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-faces-ai-integration-challenges-security-compliance-and-cost-risks-loom?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2519489079","title":"Sagimet Biosciences Advances MASH Treatment with New Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2519489079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519489079?lang=en_us&edition=fundamental","pubTime":"2025-03-13 12:11","pubTimestamp":1741839064,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has released its Q4 earnings. Here is a breakdown of the information Sagimet Biosciences, Inc. Class ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-advances-mash-treatment-with-new-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-advances-mash-treatment-with-new-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2518486722","title":"Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2518486722","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518486722?lang=en_us&edition=fundamental","pubTime":"2025-03-12 01:13","pubTimestamp":1741713180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 13:13 ET (17:13 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2518872263","title":"Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567","url":"https://stock-news.laohu8.com/highlight/detail?id=2518872263","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518872263?lang=en_us&edition=fundamental","pubTime":"2025-03-12 00:55","pubTimestamp":1741712122,"startTime":"0","endTime":"0","summary":"Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report). The ass...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sagimet-biosciences-strategic-expansion-into-acne-treatment-with-promising-fasn-inhibitor-tvb-3567?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sagimet-biosciences-strategic-expansion-into-acne-treatment-with-promising-fasn-inhibitor-tvb-3567?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2518728991","title":"Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2518728991","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518728991?lang=en_us&edition=fundamental","pubTime":"2025-03-11 22:45","pubTimestamp":1741704326,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences  said Tuesday the US Food and Drug Administration's Division of Dermatology and Dentistry has cleared its investigational new drug application for TVB-3567.The company said the clearance allows it to enter clinical development for the treatment of acne, with a first-in-human phase 1 trial planned in 2025.TVB-3567 is its second fatty acid synthase inhibitor, it said.Price: 3.37, Change: -0.17, Percent Change: -4.80","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1145","00511","SGMT","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SGMT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"SGMT","fiscalQuarterEnding":"2025/03","expectedEps":-0.79,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.56}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SGMT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SGMT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1738036800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SGMT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SGMT","date":"2025-06-02","current":-2.001146,"percent":0.926339,"low":-15.666506,"twenty":-6.763552,"median":-4.505306,"eighty":-3.09371,"high":-1.342444,"avg":-5.246632,"sd":2.854182,"marketCap":114293474},"quantilePoints":[{"date":"2023-07-21","current":-12.287206,"twenty":-13.337015,"median":-12.553129,"eighty":-11.625533,"marketCap":348354576},{"date":"2023-07-28","current":-12.208993,"twenty":-12.714826,"median":-12.49838,"eighty":-12.113574,"marketCap":346137170},{"date":"2023-08-04","current":-12.733018,"twenty":-12.595364,"median":-12.529665,"eighty":-12.271563,"marketCap":360993794},{"date":"2023-08-11","current":-12.514023,"twenty":-12.565643,"median":-12.517933,"eighty":-12.42486,"marketCap":354785056},{"date":"2023-08-18","current":-9.925184,"twenty":-12.565643,"median":-12.514023,"eighty":-12.265307,"marketCap":281388897},{"date":"2023-08-25","current":-9.359416,"twenty":-12.554693,"median":-12.471006,"eighty":-10.020915,"marketCap":262381858},{"date":"2023-09-01","current":-9.85717,"twenty":-12.553129,"median":-12.459274,"eighty":-9.809842,"marketCap":276335907},{"date":"2023-09-08","current":-10.126447,"twenty":-12.543743,"median":-12.279385,"eighty":-9.775571,"marketCap":283884818},{"date":"2023-09-15","current":-9.791891,"twenty":-12.532793,"median":-11.532454,"eighty":-9.775571,"marketCap":274505868},{"date":"2023-09-22","current":-8.282308,"twenty":-12.524972,"median":-10.126447,"eighty":-9.674388,"marketCap":232186213},{"date":"2023-09-29","current":-7.392878,"twenty":-12.517151,"median":-9.936056,"eighty":-9.403479,"marketCap":207251930},{"date":"2023-10-06","current":-5.866975,"twenty":-12.514023,"median":-9.90613,"eighty":-8.80291,"marketCap":164474765},{"date":"2023-10-13","current":-4.757227,"twenty":-12.495252,"median":-9.80821,"eighty":-7.764969,"marketCap":133364100},{"date":"2023-10-20","current":-3.729078,"twenty":-12.478045,"median":-9.791891,"eighty":-6.978354,"marketCap":104540984},{"date":"2023-10-27","current":-3.647479,"twenty":-12.474916,"median":-9.751091,"eighty":-6.462648,"marketCap":102253435},{"date":"2023-11-03","current":-3.100765,"twenty":-12.467095,"median":-9.681732,"eighty":-5.866975,"marketCap":86926858},{"date":"2023-11-10","current":-2.284775,"twenty":-12.467095,"median":-9.514454,"eighty":-4.757227,"marketCap":64051369},{"date":"2023-11-17","current":-1.981702,"twenty":-12.459274,"median":-9.396135,"eighty":-4.030995,"marketCap":53347428},{"date":"2023-11-24","current":-3.487116,"twenty":-12.32162,"median":-9.116089,"eighty":-3.455541,"marketCap":93873157},{"date":"2023-12-01","current":-3.248971,"twenty":-12.280949,"median":-8.665823,"eighty":-3.326797,"marketCap":87462307},{"date":"2023-12-08","current":-3.436085,"twenty":-12.223071,"median":-7.870232,"eighty":-3.326797,"marketCap":92499403},{"date":"2023-12-15","current":-4.74588,"twenty":-11.827315,"median":-7.466317,"eighty":-3.305106,"marketCap":127759077},{"date":"2023-12-22","current":-4.79691,"twenty":-11.412789,"median":-6.927763,"eighty":-3.326797,"marketCap":129132830},{"date":"2023-12-29","current":-5.009539,"twenty":-10.856914,"median":-6.462648,"eighty":-3.351567,"marketCap":134856803},{"date":"2024-01-05","current":-4.286601,"twenty":-10.142767,"median":-6.27497,"eighty":-3.385054,"marketCap":115395295},{"date":"2024-01-12","current":-6.055674,"twenty":-10.126447,"median":-6.038333,"eighty":-3.402064,"marketCap":163018751},{"date":"2024-01-19","current":-5.494334,"twenty":-10.061168,"median":-5.928097,"eighty":-3.422477,"marketCap":147907462},{"date":"2024-01-26","current":-11.924235,"twenty":-11.412789,"median":-6.047003,"eighty":-3.434384,"marketCap":321000405},{"date":"2024-02-02","current":-11.8484,"twenty":-11.755197,"median":-6.332089,"eighty":-3.449693,"marketCap":318958920},{"date":"2024-02-09","current":-7.10904,"twenty":-11.755197,"median":-6.72671,"eighty":-3.480312,"marketCap":191375352},{"date":"2024-02-16","current":-10.260714,"twenty":-11.412789,"median":-7.18072,"eighty":-3.487116,"marketCap":276218424},{"date":"2024-02-23","current":-7.973973,"twenty":-11.272575,"median":-7.393401,"eighty":-3.512632,"marketCap":214659353},{"date":"2024-03-01","current":-7.263069,"twenty":-10.976358,"median":-7.495026,"eighty":-3.600344,"marketCap":195521817},{"date":"2024-03-08","current":-7.642218,"twenty":-10.478725,"median":-7.466317,"eighty":-3.696438,"marketCap":205728503},{"date":"2024-03-15","current":-5.118509,"twenty":-10.189946,"median":-7.39314,"eighty":-3.910228,"marketCap":137790253},{"date":"2024-03-22","current":-5.509506,"twenty":-10.132975,"median":-7.18072,"eighty":-4.056781,"marketCap":148315897},{"date":"2024-03-28","current":-6.56,"twenty":-10.093807,"median":-7.132737,"eighty":-4.084178,"marketCap":182866572},{"date":"2024-04-05","current":-6.239442,"twenty":-10.00568,"median":-6.795721,"eighty":-4.174333,"marketCap":173930684},{"date":"2024-04-12","current":-5.976126,"twenty":-9.938231,"median":-6.56,"eighty":-4.313817,"marketCap":166590490},{"date":"2024-04-19","current":-4.545061,"twenty":-9.925184,"median":-6.397368,"eighty":-4.392065,"marketCap":126698131},{"date":"2024-04-26","current":-4.487819,"twenty":-9.917562,"median":-6.217851,"eighty":-4.458405,"marketCap":125102437},{"date":"2024-05-03","current":-5.09459,"twenty":-9.886546,"median":-6.182199,"eighty":-4.468439,"marketCap":142016797},{"date":"2024-05-10","current":-5.231972,"twenty":-9.844114,"median":-6.079163,"eighty":-4.479356,"marketCap":145846463},{"date":"2024-05-17","current":-5.429865,"twenty":-9.811474,"median":-6.018678,"eighty":-4.487871,"marketCap":151590963},{"date":"2024-05-24","current":-5.372708,"twenty":-9.791891,"median":-5.987575,"eighty":-4.491214,"marketCap":149995268},{"date":"2024-05-31","current":-6.172899,"twenty":-9.791891,"median":-5.987575,"eighty":-4.501006,"marketCap":172334989},{"date":"2024-06-07","current":-5.315552,"twenty":-9.783731,"median":-5.976126,"eighty":-4.523122,"marketCap":148399574},{"date":"2024-06-14","current":-5.47559,"twenty":-9.751091,"median":-5.952111,"eighty":-4.533251,"marketCap":152867518},{"date":"2024-06-21","current":-4.446773,"twenty":-9.731508,"median":-5.91688,"eighty":-4.519544,"marketCap":124145020},{"date":"2024-06-28","current":-4.698262,"twenty":-9.718452,"median":-5.91688,"eighty":-4.523122,"marketCap":131166075},{"date":"2024-07-05","current":-3.257919,"twenty":-9.685812,"median":-5.888477,"eighty":-4.48795,"marketCap":90954577},{"date":"2024-07-12","current":-3.738033,"twenty":-9.677652,"median":-5.800519,"eighty":-4.448199,"marketCap":104358410},{"date":"2024-07-15","current":-3.806621,"twenty":-9.67602,"median":-5.796735,"eighty":-4.447058,"marketCap":106273243},{"date":"2024-08-02","current":-3.97809,"twenty":-9.674388,"median":-5.79295,"eighty":-4.391494,"marketCap":111060326},{"date":"2024-08-09","current":-3.109312,"twenty":-9.635837,"median":-5.632964,"eighty":-4.048186,"marketCap":86805772},{"date":"2024-08-16","current":-3.011259,"twenty":-9.556995,"median":-5.529634,"eighty":-3.765468,"marketCap":88082328},{"date":"2024-08-23","current":-3.174914,"twenty":-9.5049,"median":-5.509506,"eighty":-3.626007,"marketCap":92869411},{"date":"2024-08-30","current":-3.36039,"twenty":-9.480538,"median":-5.47559,"eighty":-3.517501,"marketCap":98294771},{"date":"2024-09-06","current":-2.913065,"twenty":-9.458966,"median":-5.429865,"eighty":-3.459899,"marketCap":85210078},{"date":"2024-09-13","current":-3.709522,"twenty":-9.418167,"median":-5.410329,"eighty":-3.440029,"marketCap":108507215},{"date":"2024-09-20","current":-3.578597,"twenty":-9.3382,"median":-5.372708,"eighty":-3.459899,"marketCap":104677549},{"date":"2024-09-27","current":-3.076721,"twenty":-9.217671,"median":-5.306102,"eighty":-3.426198,"marketCap":89997161},{"date":"2024-10-04","current":-4.495067,"twenty":-9.063099,"median":-5.281258,"eighty":-3.402458,"marketCap":131485214},{"date":"2024-10-11","current":-4.516888,"twenty":-9.008144,"median":-5.226248,"eighty":-3.408396,"marketCap":132123492},{"date":"2024-10-18","current":-5.891593,"twenty":-8.972181,"median":-5.273199,"eighty":-3.426198,"marketCap":172334989},{"date":"2024-10-25","current":-6.000697,"twenty":-8.935294,"median":-5.292689,"eighty":-3.429281,"marketCap":175526378},{"date":"2024-10-31","current":-5.826131,"twenty":-8.894301,"median":-5.311818,"eighty":-3.436085,"marketCap":170420156},{"date":"2024-11-08","current":-6.753511,"twenty":-8.791513,"median":-5.372708,"eighty":-3.436763,"marketCap":197546960},{"date":"2024-11-15","current":-5.651565,"twenty":-8.755967,"median":-5.41811,"eighty":-3.453095,"marketCap":165313934},{"date":"2024-11-22","current":-3.861691,"twenty":-8.665823,"median":-5.372708,"eighty":-3.487116,"marketCap":144879052},{"date":"2024-11-29","current":-4.882893,"twenty":-8.557843,"median":-5.315552,"eighty":-3.487116,"marketCap":183191513},{"date":"2024-12-06","current":-3.998995,"twenty":-8.332016,"median":-5.292689,"eighty":-3.504949,"marketCap":150030307},{"date":"2024-12-13","current":-3.896017,"twenty":-8.272608,"median":-5.273199,"eighty":-3.525595,"marketCap":146166866},{"date":"2024-12-20","current":-4.350838,"twenty":-8.042693,"median":-5.190447,"eighty":-3.550034,"marketCap":163230399},{"date":"2024-12-27","current":-4.35942,"twenty":-7.978712,"median":-5.107971,"eighty":-3.56885,"marketCap":163552352},{"date":"2025-01-03","current":-3.853109,"twenty":-7.96022,"median":-5.094591,"eighty":-3.578236,"marketCap":144557099},{"date":"2025-01-10","current":-4.608284,"twenty":-7.932249,"median":-5.088866,"eighty":-3.585335,"marketCap":172889002},{"date":"2025-01-17","current":-3.664315,"twenty":-7.891035,"median":-5.014451,"eighty":-3.578519,"marketCap":137474123},{"date":"2025-01-24","current":-3.561337,"twenty":-7.843641,"median":-5.001034,"eighty":-3.577995,"marketCap":133610681},{"date":"2025-01-31","current":-3.484103,"twenty":-7.800873,"median":-4.931489,"eighty":-3.565628,"marketCap":130713100},{"date":"2025-02-07","current":-4.041903,"twenty":-7.796247,"median":-4.899965,"eighty":-3.577995,"marketCap":151640074},{"date":"2025-02-14","current":-3.775875,"twenty":-7.711114,"median":-4.882893,"eighty":-3.5785,"marketCap":141659518},{"date":"2025-02-21","current":-3.454068,"twenty":-7.655997,"median":-4.848447,"eighty":-3.56477,"marketCap":129586263},{"date":"2025-02-28","current":-3.097934,"twenty":-7.585345,"median":-4.824006,"eighty":-3.534402,"marketCap":116225195},{"date":"2025-03-07","current":-3.13226,"twenty":-7.533213,"median":-4.786117,"eighty":-3.487116,"marketCap":117513009},{"date":"2025-03-14","current":-2.479989,"twenty":-7.4778,"median":-4.774032,"eighty":-3.471231,"marketCap":113005660},{"date":"2025-03-21","current":-2.861526,"twenty":-7.417463,"median":-4.751553,"eighty":-3.434384,"marketCap":130391147},{"date":"2025-03-28","current":-2.656626,"twenty":-7.395771,"median":-4.728869,"eighty":-3.400275,"marketCap":121054497},{"date":"2025-04-04","current":-1.603868,"twenty":-7.392983,"median":-4.702859,"eighty":-3.36039,"marketCap":73083433},{"date":"2025-04-11","current":-1.575606,"twenty":-7.289031,"median":-4.694849,"eighty":-3.31696,"marketCap":71795619},{"date":"2025-04-17","current":-1.42723,"twenty":-7.21366,"median":-4.648098,"eighty":-3.301626,"marketCap":65034596},{"date":"2025-04-25","current":-2.204435,"twenty":-7.173257,"median":-4.603993,"eighty":-3.254074,"marketCap":100449476},{"date":"2025-05-02","current":-2.77674,"twenty":-7.146955,"median":-4.575776,"eighty":-3.219588,"marketCap":126527705},{"date":"2025-05-09","current":-1.80385,"twenty":-7.118519,"median":-4.541885,"eighty":-3.18279,"marketCap":103025104},{"date":"2025-05-16","current":-1.865858,"twenty":-6.931314,"median":-4.533251,"eighty":-3.143037,"marketCap":106566591},{"date":"2025-05-23","current":-1.922228,"twenty":-6.7923,"median":-4.516125,"eighty":-3.120362,"marketCap":109786126},{"date":"2025-05-30","current":-1.972961,"twenty":-6.768572,"median":-4.505306,"eighty":-3.099066,"marketCap":112683707},{"date":"2025-06-02","current":-2.001146,"twenty":-6.763552,"median":-4.505306,"eighty":-3.09371,"marketCap":114293474}],"updateTime":1749010413545}}}